Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US relaxes safety warnings for imaging agents

This article was originally published in Scrip

Executive Summary

The US FDAis notifying healthcare professionals that it has eased recent warnings for micro-bubble contrast agents. Last October it requested Lantheus Medical Imaging's Definity (perflutren lipid microspheres) and GE Healthcare's Optison (perflutren protein-type A microspheres) add "black box" warnings about the risk of serious cardiopulmonary reactions and death. The labels also added a recommendation to monitor all patients for at least 30 minutes post-administration and new contraindications for certain cardiopulmonary conditions. The FDA now has deleted many of those contraindications and eased the boxed warning to recommend intensive 30-minute monitoring only for patients with pulmonary hypertension or unstable cardiopulmonary conditions. The manufacturers must conduct postmarketing clinical and epidemiological studies to better assess the risks. Since October the agency received reports of five deaths with Definity, all in patients with severe underlying medical conditions, and none with Optison.

Topics

Related Companies

UsernamePublicRestriction

Register

SC031076

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel